Friday, 20 Apr 2018

You are here

Treat-to-Target in Spondyloarthropathies

Today's session, Treat to target in axSpA: reality or utopia?, was opened with a presentation by Dr. Jurgen Braun (Herne, Germany), who masterfully reintroduced us to the treat-to-target concept in spondyloarhtropathies.

Similar to how diabetes control and outcomes improved with introduction of treat to target concept in endocrinology, rheumatologists are looking to adopt similar strategies for more effective management of rheumatic disease outcomes.

In his presentation today Dr. Braun raised two important questions:

  1. what is the target in treatment of rheumatic diseases? and

  2. is T2T applicable in SpA?

While more easily defined in rheumatoid arthritis, remission is a more complicated target in SpA with axial involvement. The majority of published studies conclude that overall mortality and morbidity in SpA is linked to disease activity. Longitudinal relationship as observed between disease activity and radiographic damage over time:

Existent treatment guidelines are helpful in achieving treatment. When used in T2T approach, ASDAS showed to be effective outcome measure in axSpA comparable to DAS in RA.

 

Dr. Braun concluded that T2T can be effectively used in SpA and patients would benefit if rheumatologists follow this concept.

Add new comment

More Like This

The RheumNow Week in Review – Vitamin D Snark Report (4.20.18)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.  A second life for Syk kinase, Vitamin D talk, VTE, regulatory hearings and the Lupus clinic edge.

RheumNow Week in Review - Do you Dig Shingrix? (4.6.2018)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Highlights includes manpower shortfalls, comorbidities in AA Lupus, certolizumab pregnancy safety, which Shingles vaccine is best and the power of combination biologics in severe refractory  SLE.

"Breakthrough" Drug Designation by the FDA

The current issue of the NEJM reviews the Food and Drug Administration (FDA) “breakthrough therapy” designation that was introduced in 2012 to expedite testing and approval of medications that were intended to treat serious or life-threatening conditions.  This status is granted when preliminary evidence with a new drug suggests substantial benefits over existing therapies for these unfortunate conditions.

ACR Projects Significant Manpower Shortages for 2030

Arthritis & Rheumatology has published the results of the 2015 Workforce Study of Rheumatology Specialists, and estimates a current shortage (demand > supply) of 700 (12.9%) full-time rheumatologists and that this deficit will worsen (102%) to 4133 FTE by 2030.

RheumNow Week in Review -The Temporal Artery Biopsy Letdown (4.6.2018)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. News on the cost of RA care, infections on planes, CV events and Sacroiliitis in IBD, NXP-2 antibodies and calcinosis and rituximab in myositis ILD patients.